Linezolid and vancomycin have similar efficacy
and safety profiles.
▪ The near-zero efficacy difference between both
antibiotics demonstrates that no drug is superior
for the treatment of hospital-acquired pneumonia.
▪ Our results remained consistent across different
patient populations and study designs for both
clinical response and mortality outcomes.
▪ Randomised controlled trials set selective inclusion
criteria that can limit their generalisability to
unselected populations.